Indian Journal of Clinical Biochemistry最新文献_第2页

Persistence of SARS-CoV-2 Antibodies for a Year Following SARS-CoV-2 Vaccinations (BBV152 and ChAdOx1 nCoV-19). 接种SARS-CoV-2疫苗（BBV152和ChAdOx1 nCoV-19）后一年SARS-CoV-2抗体的持久性

IF 1.5

Indian Journal of Clinical Biochemistry Pub Date : 2025-01-01 Epub Date: 2023-09-07 DOI: 10.1007/s12291-023-01149-w

Tanima Dwivedi, Apurva Raj, Nupur Das, Ritu Gupta, Sushma Bhatnagar, Anant Mohan, Randeep Guleria

{"title":"Persistence of SARS-CoV-2 Antibodies for a Year Following SARS-CoV-2 Vaccinations (BBV152 and ChAdOx1 nCoV-19).","authors":"Tanima Dwivedi, Apurva Raj, Nupur Das, Ritu Gupta, Sushma Bhatnagar, Anant Mohan, Randeep Guleria","doi":"10.1007/s12291-023-01149-w","DOIUrl":"10.1007/s12291-023-01149-w","url":null,"abstract":"The first two vaccines administered in the COVID-19 vaccination campaign of India were Covaxin (BBV152) and Covishield (ChAdOx1-nCoV-19). In this study, we evaluate the longevity and sustainability of the humoral immune response after vaccination and various factors influencing it. An observational study was conducted in individuals who received both doses of Covaxin or Covishield vaccine, and their blood samples were analyzed for total-antiRBD-SARS-CoV-2 antibodies. Then, antibody titers were classified based on monthly time-intervals up to 360 days and their trend was analyzed. In addition, the correlation between antibody titers and factors such as previous SARS-CoV-2-infection status, vaccine type and presence of comorbidities was examined. Of the 2069 participants, most (1767;85.4%) had been vaccinated with Covaxin, but the higher antibody titers were induced by Covishield vaccine at all time points. However overall, antibodies persisted for at least 1 year, although a drop in antibody titers occurred in the 3rd and 6th months. In addition, 430 (20.8%) participants had prior SARS-CoV-2 infection (hybrid immunity) with a significantly higher humoral immune response compared with vaccine-induced immunity (naive immunity). No significant differences were observed in antibody titers related to age, sex and presence of comorbidities. We concluded that vaccine-mediated immunity lasts for at least one year. However, antibody titers decrease over time, which may be more pronounced in certain groups such as Covaxin vaccine, vaccine-induced-immunity, presence of comorbidities and > 60 years which should be considered when recommending booster vaccination, as these individuals may have a stronger and longer-lasting immune response to the virus.","PeriodicalId":13280,"journal":{"name":"Indian Journal of Clinical Biochemistry","volume":"4 1","pages":"111-120"},"PeriodicalIF":1.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11741955/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76127503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Combination Therapy of Curcumin and Cisplatin Encapsulated in Niosome Nanoparticles for Enhanced Oral Cancer Treatment. 纳米粒包封的姜黄素和顺铂联合治疗口腔癌。

IF 1.5

Indian Journal of Clinical Biochemistry Pub Date : 2025-01-01 Epub Date: 2024-11-11 DOI: 10.1007/s12291-024-01279-9

Elham Saberian, Janka Jenčová, Andrej Jenča, Andrej Jenča, Adriána Petrášová, Jozef Jenča, Azim Akbarzadehkhayavi

{"title":"Combination Therapy of Curcumin and Cisplatin Encapsulated in Niosome Nanoparticles for Enhanced Oral Cancer Treatment.","authors":"Elham Saberian, Janka Jenčová, Andrej Jenča, Andrej Jenča, Adriána Petrášová, Jozef Jenča, Azim Akbarzadehkhayavi","doi":"10.1007/s12291-024-01279-9","DOIUrl":"10.1007/s12291-024-01279-9","url":null,"abstract":"Oral cavity cancer poses a significant health threat due to its aggressive nature and limited responsiveness to traditional therapies like chemotherapy and radiation, highlighting the need for more effective treatment options. To address this, researchers have explored a novel approach using niosome nanoparticles to co-encapsulate curcumin (CUR) and cisplatin (Cis), to enhance therapeutic efficacy. While CUR has anti-cancer properties, its poor bioavailability limits its effectiveness. Cis, on the other hand, is hindered by severe side effects and resistance. A dual-drug delivery system that encapsulates both CUR and Cis in niosome nanoparticles seeks to leverage the synergistic effects of these agents to improve treatment outcomes. The study synthesized Cis and CUR co-loaded nanoparticles (Cis/CUR-NPs) using reverse microemulsion and film dispersion methods, resulting in nanoparticles with an average size of 220.9 nm and a consistent size distribution. In vitro experiments demonstrated that the nanosized Cis/CUR-NPs could release both Cis and CUR, achieving a synergistic effect on OECM-1 cells at an optimal ratio (1:6) of the two drugs. Overall, the findings suggest that Cis/CUR-NPs offer a promising and effective strategy for leveraging the synergistic effects of Cis and CUR in treating oral cancer.","PeriodicalId":13280,"journal":{"name":"Indian Journal of Clinical Biochemistry","volume":"40 1","pages":"59-66"},"PeriodicalIF":1.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11741963/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143004824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unmasking Lead Exposure and Neurotoxicity: Epigenetics, Extracellular Vesicles, and the Gut-Brain Connection. 揭露铅暴露和神经毒性：表观遗传学、细胞外囊泡和肠脑连接。

IF 1.5

Indian Journal of Clinical Biochemistry Pub Date : 2025-01-01 Epub Date: 2025-01-07 DOI: 10.1007/s12291-025-01299-z

Shruti Gupta, Prasenjit Mitra, Praveen Sharma

引用次数: 0

Correction: Cross Sectional Study of Vitamin D Levels in Western Rajasthan and Meta-Analysis for Estimation of Vitamin D Levels. 更正：拉贾斯坦邦西部维生素D水平的横断面研究和维生素D水平估计的荟萃分析。

IF 1.5

Indian Journal of Clinical Biochemistry Pub Date : 2025-01-01 Epub Date: 2024-11-05 DOI: 10.1007/s12291-024-01272-2

Surjit Singh, Divesh Jalan, Pankaj Bhardwaj, Praveen Sharma, Abhay Elhence

引用次数: 0

Double Trouble: Unravelling the Health Hazards of Microplastics and Heavy Metals. 双重麻烦：解开微塑料和重金属对健康的危害。

IF 1.5

Indian Journal of Clinical Biochemistry Pub Date : 2024-10-01 Epub Date: 2024-09-20 DOI: 10.1007/s12291-024-01270-4

Prasenjit Mitra, Shruti Gupta, Praveen Sharma

引用次数: 0

Study of Glabranin as an Inhibitor Against Prostate Cancer: Molecular Docking, Molecular Dynamics Simulation, MM-PBSA Calculation and QSAR Prediction. Glabranin作为前列腺癌抑制剂的研究：分子对接、分子动力学模拟、MM-PBSA计算和QSAR预测。

IF 1.5

Indian Journal of Clinical Biochemistry Pub Date : 2024-07-01 Epub Date: 2023-04-01 DOI: 10.1007/s12291-023-01134-3

Rene Barbie Browne, Nabajyoti Goswami, Probodh Borah, Jayanti Datta Roy

{"title":"Study of Glabranin as an Inhibitor Against Prostate Cancer: Molecular Docking, Molecular Dynamics Simulation, MM-PBSA Calculation and QSAR Prediction.","authors":"Rene Barbie Browne, Nabajyoti Goswami, Probodh Borah, Jayanti Datta Roy","doi":"10.1007/s12291-023-01134-3","DOIUrl":"10.1007/s12291-023-01134-3","url":null,"abstract":"Prostate cancer is the World's second most frequent malignancy, with the fifth-highest male mortality rate. In advanced prostate cancer patients, point mutations such as T877A and W741L are prevalent, imparting treatment resistance and hence promoting cancer development. The emergence of drug resistance in prostate cancer necessitates the development of suitable ligands to allow for stronger interactions with the receptors, which can inhibit cancer progression. The present study focuses on flavonoids produced by plants, which may act as inhibitors of point mutations like T877A and W741L in prostate cancer. This research was conducted using an in-silico method where the compound Glabranin and its derivatives were virtually screened to identify potential drugs for combating such point mutations. Thirty-five Molecular Dockings were performed to find the ligand-receptor complexes with the lowest binding energy. Moreover, employing a variety of tools, ligands were evaluated for drug-likeness and toxicity, indicating a promising drug candidate. Based on the results of Molecular Docking, Drug-likeness, and ADMET testing, eight structures were subjected to a 100 ns Molecular Dynamics simulation. A QSAR analysis was also performed based on the simulation findings. In this study, it was revealed that GlaMod2 phytocompound was effective against T877A and W741L mutations in prostate cancer. It was observed that the phytocompound was stable and had potential properties for the development of a novel drug to combat prostate cancer and drug resistance This phytocompound may therefore be effective in the development of prostate cancer inhibitors for patients with mutant androgen receptors.Graphical abstract: Supplementary information: The online version contains supplementary material available at 10.1007/s12291-023-01134-3.","PeriodicalId":13280,"journal":{"name":"Indian Journal of Clinical Biochemistry","volume":"262 1","pages":"331-343"},"PeriodicalIF":1.5,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11615236/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82971789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

New Perspectives on Selenium and Selenoproteins in Cardiomyopathy. 心肌病中硒和硒蛋白的新视角。

IF 1.5

Indian Journal of Clinical Biochemistry Pub Date : 2024-07-01 Epub Date: 2024-06-26 DOI: 10.1007/s12291-024-01246-4

Rajendra Prasad, Sonia Deswal, Munish Kumar

引用次数: 0

The Hepatocurative Effects of Zanthoxylum zanthoxyloides Alkaloids on Tetrachloromethane-Induced Hepatotoxicity on Albino Rats. Zanthoxylum zanthoxyloides 生物碱对四氯甲烷诱导的白化大鼠肝毒性的杀肝作用

IF 1.5

Indian Journal of Clinical Biochemistry Pub Date : 2024-04-01 Epub Date: 2022-11-12 DOI: 10.1007/s12291-022-01095-z

Thecla Okeahunwa Ayoka, Ngwu Nwachukwu, Aloysius Chinedu Ene, Chidi Uzoma Igwe, Charles Okeke Nnadi

{"title":"The Hepatocurative Effects of Zanthoxylum zanthoxyloides Alkaloids on Tetrachloromethane-Induced Hepatotoxicity on Albino Rats.","authors":"Thecla Okeahunwa Ayoka, Ngwu Nwachukwu, Aloysius Chinedu Ene, Chidi Uzoma Igwe, Charles Okeke Nnadi","doi":"10.1007/s12291-022-01095-z","DOIUrl":"10.1007/s12291-022-01095-z","url":null,"abstract":"The study investigated the hepatocurative activity of the bulk alkaloids of Zanthoxylum zanthoxyloides in a tetrachloromethane (CCl4)-induced hepatotoxicity model in rats. The hepatocurative activity of the alkaloids at 200, 400 and 600 mg/kg doses was demonstrated by the assay of both enzymic and non-enzymic parameters. Sections of the liver were also subjected to histological examinations. Mapping techniques and data visualization approaches were adopted in finding relationships between the enzymic and non-enzymic parameters and the treatment groups. The bulk alkaloids caused dose-dependent effects on both the enzymic and non-enzymic parameters. The bulk alkaloids elicited a significant reduction (p < 0.05) in all liver and antioxidant enzymes activities compared with the untreated. The 600 mg/kg dose caused the restoration of the ALP, ALT and AST to 76.16, 10.72 and 11.83 iU/L respectively similar to the standard butylated hydroxytoluene. The 600 mg/kg dose also caused a slight increase in the activities of SOD, catalase and GPx to 11.45. 1.37 and 11.66 iU/L respectively when compared with the untreated rats. In the non-enzymic assays, the 600 mg/kg dose elicited a significant (p < 0.05) upregulation in the total bilirubin (1.18 mg/100 mL), total protein (3.75 g/dL), HDL (1.80 mMol/L) and vitamin C (2.41 mg/dL) and decrease in the CHOL (3.35 g/dL), TAG (1.85 mMol/L), LDL (0.67 mMol/L), BUN (39.55 mg/dL) and MDA (1.13 nMol/mL) when compared with the untreated rats. The restoration of the natural histo-architecture of the CCl4-damaged liver by the alkaloids further evidenced the hepatocurative activity of the bulk alkaloids.","PeriodicalId":13280,"journal":{"name":"Indian Journal of Clinical Biochemistry","volume":"39 2","pages":"188-196"},"PeriodicalIF":1.5,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10987411/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140858710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Phenotypic Evolution in Fabry Disease: Our Experience in Indian Cohort 法布里病的表型演变：我们在印度队列中的经验

IF 2.1

Indian Journal of Clinical Biochemistry Pub Date : 2024-01-10 DOI: 10.1007/s12291-023-01176-7

Usha Dave, Srilatha Kadali, Tajamul Hussain, Ananthaneni Radhika, Sagar Patel, Nirav Patel, S. Naushad

引用次数: 0

miR-335-5p Inhibits EMT and PI3K/AKT Pathways via MARCH8 miR-335-5p 通过 MARCH8 抑制 EMT 和 PI3K/AKT 通路

IF 2.1

Indian Journal of Clinical Biochemistry Pub Date : 2024-01-08 DOI: 10.1007/s12291-023-01175-8

Arjumand Bano, Geetika Suyal, A. Saraya, Rinu Sharma

引用次数: 0